A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Breast · Metastatic · Triple Negative · Cancer · Disseminated Tumor Cell
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Los Angeles General Medical Center, Los Angeles, California, United States
Contact: Principal Investigator (Anastasia Martynova, MD)USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Contact: Principal Investigator (Anastasia Martynova, MD)UF Health, Gainesville, Florida, United States
Study leads
Anastasia Martynova, MD
Principal Investigator
University of Southern California